CureMatch, Inc.

Fantastic share by the @American Cancer Society Journals of this paper by our CureMatch, Inc. founder & colleagues. The average tumor has 5 genomic alterations, and if there are about 700 cancer genes, that means greater than one trillion patterns. This is beyond human cognition, and where #ArtificialIntelligence becomes a critical part of #precisiononcology

Earlier this year, Kate Sasser, our Chief Scientific Officer, participated in a panel at CES 2025 titled 'The Rise of Personalized Medicine: Genomics and Beyond,' where she joined other industry leaders to discuss advancements in genomics, #AI, and the future of personalized care. Access a recording of the panel here: https://bit.ly/4kkOblt

Colorectal cancer is the second leading cause of cancer death in the United States. But when caught early, it can often be cured. That’s why we prioritize timely colorectal cancer screening. https://k-p.li/3QyVTKa #ColorectalCancerAwarenessMonth

Growing our portfolio to serve patients and providers.

This is fantastic! The average tumor has 5 genomic alterations, and if there are about 700 #cancer genes and ~300 drugs, that means greater than one trillion patterns connecting cancer markers to therapy options. With false positives from CH the clinical picture can get needlessly more complex and treatment options more obscured. Where CureMatch, Inc. analysis is useful is after the NGS. We are lab agnostic and have received many Caris Life Sciences outputs as our input. When something is deemed by the NGS lab as a CH marker we exclude it from therapy matching and scoring on our reports. #ArtificialIntelligence #PrecisionMedicine #oncology

#ESMOTAT25: The transformative odyssey of #TumourAgnostic #DrugDevelopment in #PrecisionMedicine. Vivek Subbiah, MD discusses the paradigm shift away, at least partially, from organ-based treatment to molecularly guided treatment across tumour types. He describes how regulatory shifts and greater access to tumour profiling are now needed to realise their full benefits for patients. To learn more, read the Opinion piece in the #ESMODailyReporter 🔗 https://ow.ly/9ooh50Va9Yi

  As the leader in genomic testing in Israel, Oncotest prides itself with making the most innovative genomic tests and analysis's available for Israeli physicians as well as investing in their education on advancements in the field. Oncotest recently hosted a webinar, moderated by Professor Raanan Berger (Director of the Jusidman Cancer Center at the Sheba Medical Center), on the topic of the CureMatch, Inc. Solution for Navigating Molecular Cancer Complexity. We gained insights from Prof. Razelle Kurzrock, MD, FACP (Co-Founder, Board of Directors, and Chief Medical Officer at CureMatch, Inc.) as she discussed how CureMatch assists in personalizing cancer treatment. In addition to Prof. Berger and Prof. Kurzrock, we had the privilege of hearing from Dr. Hadas Gantz-Sorotsky, (Senior Medical Oncologist, The Jusidman Center at the Sheba Medical Center Hospital) about a case where the CureMatch analysis helped determine a patients treatment plan. Learn how the platform matches patient's unique molecular markers to FDA/EMA-approved drugs and enables tailored drug combinations which help address as many biomarkers as possible in order to individualize the fight with each patient’s cancer in the video below: https://lnkd.in/dY-ZSv_G   #genomics #analysis #personalized_treatment #oncology

I cannot overstate the importance of Larry Ellison's vision and leadership. This investment won't just secure hundreds of thousands of American jobs—it will transform the quality and efficiency with which healthcare is delivered around the world.

We determine “molecular eligibility” of a #patient to #clinicaltrials by evaluating NGS profiles of patients and matching them with clinical trials that have highly ranked drugs or combinations for each patient’s cancer. The assessment of impact of a #therapy tested in the clinical trial on the patient’s molecular profile is based on the number and types of clinically significant #biomarkers in the molecular profile and their interaction between each other and the drug(s) of the trial therapy. #cancertreatment #Oncology #artificialintelligence